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Aortic valve replacement is the gold standard for the management of patients with severe 
aortic stenosis or mixed pathology that is not amenable to repair according to currently 
available guidelines. Such a simplified approach may be suitable for many patients, but it is far 
from ideal for young adults considering emerging evidence demonstrating that conventional 
valve replacement in this cohort of patients is associated with inferior long-term survival when 
compared to the general population. Moreover; the utilisation of mechanical and bioprosthetic 
valves can significantly impact on quality and is linked to increased rates of morbidities. 
Other available options such as stentless valve, homografts, valve reconstruction and Ross 
operation can be an appealing alternative to conventional valve replacement. Young patients 
should be fully informed about all the options available - shared decision making is now part 
of modern informed consent. This can be achieved when referring physicians have a better 
understanding of the short and long term outcomes associated with every intervention, in 
terms of survival and quality of life. This review presents up to date evidence for available 
surgical options for young adults with aortic stenosis and mixed disease not amenable to 
repair.
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intRoDuction
Current guidelines recommend prosthetic valves replacement as the gold standard for the management of 
patients with severe AS or mixed pathology while dividing recommendations based on single age cut off 
(1, 2). Such a simplified approach may be suitable for many patients but it is far from ideal for young adults.
It is recognised that aortic pathology differs between age groups. In fact, younger people have high 
incidence of bicuspid valves, sometimes associated with additional aortopathy. Furthermore; some young 
patients have a small annulus which creates its own set of problems. Prosthetic valve replacement may not 
be the best option for young adults as it can be associated with complications such as thromboembolism, 
bleeding and limited durability. Moreover; the use of prosthetic valves in such patients can lead to 
prosthetic-patient mismatch when annular enlargement is not performed which may in severe cases 
potentially impact adversely on long term outcomes (3, 4). Importantly, most long-term studies of AVR 
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include heterogeneous cohorts which makes their results challenging 
to extrapolate to young adults specifically.
This review of literature based on published article focuses on 
the surgical options for young adults (<65 years) with aortic stenosis 
and/or mixed disease not amenable to repair and discusses stented 
and stentless valves, valvuloplasty, homografts, the Ross operation 
and complete valve reconstruction. We aim to provide a balanced 
over view of available data and discuss important papers of interest.
SuRgicAl optionS
Stented tissue or Mechanical valve 
Replacement
The use of stented prostheses in young adults undergoing AVR is 
not without its drawbacks as these valves may have a suboptimal 
haemodynamic profile alongside the problem of rapid degeneration 
for tissue prostheses and the need for life long anticoagulation with 
mechanical valves. Some studies reported that AVR results in normal 
long-term survival, with low rates of prosthesis-related complications 
(5, 6). Such studies however included a wide range of ages or did not 
subdivide patients by age. A closer look at reports in young adults 
shows a different picture.
Bouhout et al. (7) reported 450 consecutive adults <65 years 
(53 ± 9 years) who underwent elective isolated mechanical AVR, 
with an overall survival at 1, 5, and 10 years of 98, 95 and 87% 
respectively, lower than expected for the age- and gender-matched 
local general population (Figure  1). Actuarial freedom from 
prosthetic valve dysfunction was 99, 95 and 91% at 1, 5, and 10 
years, with freedom from reoperation at 10 years of 82%. Freedom 
from major haemorrhage was 98, 96 and 90% at 1, 5 and 10 years. 
It appears that normal life expectancy is not restored in young 
adults and there is a low but constant hazard of prosthetic valve 
reintervention.
Ruel et al. (8) examined 500 young adults (18–50 years) who 
had AVR (n = 309) and/or mitral valve replacement (mean age in 
AVR 39.1 ± 8.1, MVR 41.5 ± 6.7 and combined valve replacement 
42.1 ± 6.1). 5, 10 and 15 year survival was 92, 88 and 80% after AVR. 
The ten-year cumulative incidence of embolic stroke was 6.3% for 
mechanical AVR vs 6.4% for bioprosthetic AVR patients. Freedom 
from recurrent heart failure, and freedom from disability were 
significantly higher in bioprosthetic than mechanical valve patients. 
Furthermore, career or income limitations, higher prevalence of 
disability and poorer disease perception were more often linked to 
a mechanical prosthesis.
With the documented improved durability of contemporary 
bioprostheses, there has been a massive shift towards using them 
in younger patients (9). However, long-term outcomes of patients 
younger than 60 years old are not well known. Forcillo et al. 
(10) in a series of 144 AVR patients <60 years (51 ± 9), showed 
actuarial survival rates of 89, 79 and 57% after 5, 10 and 15 years 
of follow-up, respectively. This too was lower than a gender- and 
age-matched general population at all time points. At 5, 10 and 
15 years freedom from major adverse cardiac events was 89, 87 and 
75% whereas freedom from prosthetic valve dysfunction was 97, 84 
and 57%. Similarly, Welke et al. (11) reported 2,168 patients who 
had a Carpentier-Edwards aortic valve looking specifically at the 
effect of age, which was the independent variable most significantly 
associated with re-operation. There was an early hazard phase for 
patients between 21–49 years of age, such that the freedom from 
re-operation was 89% at 3 years. By 10 years this was only 58% 
in 21–49 years old, compared with 68% for 50–64 years, 93% for 
65–74 years, and 99% for patients >75 years.
The phenomenon of higher mortality after AVR was observed in 
a national cohort in Sweden by Kvidal et al in 2359 patients (mean 
age 63.2 years for male and 67.4 years for female) (12) the observed 
vs expected death ratios being higher in younger patients.
It is important however to point that these studies investigating the 
impact of stented valve replacement on long-term outcomes almost 
always contain a wide range of ages, thus extrapolation of strong 
conclusions to young adults cohort should be taken with cautious 
as such heterogeneity can impact on results. Additionally the rapid 
development of new stented valves with superior leaflet preparation 
and well as dilatable sewing rings may in the future provide an 
acceptable valve substitute for the younger patients that can improve 
outcomes (13).
the Ross operation
The Ross operation is an appealing underutilised option for valve 
replacement in young adults (14, 15), perhaps due to concerns about 
operative risk and the perceived need for reintervention. Although 
it is technically more complex, it does have excellent short and long-
term outcomes.
Skillington et al. (16) presented a large series of 324 adults 
undergoing a Ross operation of whom 204 patients [mean age 
of 41.3 years (16–62)] underwent this procedure for either AS or 
mixed pathology. There was no early mortality and at 15 years 
results showed 98% survival, 99% freedom from re-operation on the 
aortic valve and 97% freedom from re-operations on the aortic and 
pulmonary valves.
David et al. (17) demonstrated excellent results in 212 patients 
who underwent the Ross operation with a mean age of 34 ± 9 years. 
Survival at 20 years was 93.6%, similar to the matched general 
FiguRe 1 |  Survival in young adults undergoing isolated mechanical AVR 
compared to sex and age matched population (Bouhout et al.) (7) (printed 
with permission from JTCVS).
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population. Freedom from reoperation on the autograft was 81.8% 
and on the pulmonary homograft was 92.7%, and in both was 79.9% 
at 20 years (Figure 2A, B). Similar results were obtained from the 
German Ross registry (18), which included 1,779 adult patients 
(mean age 44.7 ± 11.6 years) with mean follow up of 8.3 years (range 
0–24.3 years). In this study, the early mortality was 1.1% and 
late survival of the adult population was comparable with the 
matched general population. Overall freedom from reoperation 
was 94.9, 91.1 and 82.7% at 5, 10 and 15 years. Freedom from 
autograft reoperation was 96.8, 94.7 and 86.7% and freedom 
from homograft reoperation was 97.6, 95.5 and 92.3%, at 5, 10 
and 15 years.
The recent analysis of the UK national audit included a 3-way 
propensity-matched comparison and indicated superiority of the 
Ross over both mechanical and tissue AVR, bioprostheses being 
associated with the worst outcomes (19).
These series reinforce previously published results showing low 
hospital mortality and excellent long-term survival with the Ross 
operation (17, 19, 20). One of its advantages is the diminished 
risk of thromboembolism and no need for anticoagulation 
which impacts positively on quality of life (21, 22). Moreover, 
it is able to accommodate different aortic pathologies except 
for severe connective tissue disorders and certain rheumatic 
patients (23–28).
As for the mechanism underlying these outcomes, it remains 
speculative. It is possible that there are several factors at play as the 
differences in survival are hard to explain only by attrition related to 
anticoagulation in the mechanical valves or structural degeneration in 
tissue valves. Pibarot (29) elegantly showed how the autograft retains 
a remarkable ability to eliminate a transvalvular gradient even at peak 
exercise so its physiological properties are likely to be an important 
reason. Moreover; this has been recently supported by a met-analysis 
comparing valve haemodynamics in conventional AVR compared 
to Ross (30).
Reintervention remains the main concern as there is a 
perception that the rates are high and this may be associated with 
increased morbidity and mortality (14, 15). Reports on outcomes 
of reintervention after Ross however persistently demonstrated 
that it can be performed safely and that the autograft itself 
can sometimes be salvaged by repair or even valve-sparing 
reimplantation (31–33).
There are several methods for implanting the autograft, including 
subcoronary insertion, the inclusion technique and the free-standing 
root (with its own variations, but overall the most common variant). 
All of these provide comparable outcomes and the choice seems to be 
operator-dependent to an extent (16, 34). It should be noted that the 
procedure can be complemented by Kono annular enlargement which 
deals effectively with a small annulus or left ventricular outflow tract 
(35, 36). It is perhaps conceivable that some conventional AVRs end 
up with potentially severe patient-prosthetic mismatch with adverse 
consequences for function and survival, especially in younger patients 
(3, 4, 37). In terms of the pulmonary conduit, there is no complications-
free option which is one of the major draw-backs of Ross operation 
considering that it potentially creates double valve disease specially 
in the pulmonary position which is usually replaced with pulmonary 
homograft treated or freshly decellularised homografts. In fact, when 
available, the use of freshly decellularised pulmonary homografts can 
be associated with improved freedom from reoperation as well as 
exhibiting adaptive growth both at early and mid-term (38, 39) which 
is pivotal when considering the correct conduit to use in young adults. 
The limited availability of pulmonary homografts resulted in using 
different prosthetic, or composite conduits for RV-PA reconstruction, 
which perform generally well and do not impact negatively on 
outcomes (40–42).
Although the Ross operation has good results in the right subset 
of patients, it is important to point that it still can be associated 
with considerable early and late mortality as been demonstrated by 
Etnel et al. (43) in a recent meta-analysis reporting outcome after 
paediatric aortic valve replacement (mean age 9.4 years for Ross) 
which showed that the Ross operation still associated with suboptimal 
early and late outcomes. Furthermore; the Ross procedure was also 
associated with a substantial reoperation rate in the first postoperative 
decade, and a further increase in reoperation rates is to be expected 
in the second postoperative decade. Interestingly, it seems that for 
neonates and infants undergoing the Ross procedure, aortic valve 
reoperation rates seem to be lower, whereas RV related reoperation 
rates are 2 times higher compared with older children after the 
Ross procedure.
FiguRe 2 | (A) Survival estimates of patients who underwent the Ross 
procedure, including those who no longer had the pulmonary autograft (black 
solid line) with 95% confidence limits (black dotted line) and that of the 
general population matched for age and sex (dotted blue line). (B) 
Reoperation-free survival and the competing risks for any reoperation on the 
pulmonary autograft or homograft and death (David et al.) (pernited with 
permission from JTCVS) (17).
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Homografts and Stentless valves
The use of a homograft as a valve substitute in young adults requiring 
AVR has multiple advantages, including excellent haemodynamics 
and good resistance to infection, without the need for anticoagulation. 
However, there are problems such as the lack of capacity for growth 
of the valve, the limited supply and functional deterioration requiring 
reintervention.
There is limited data in young adults and most available series 
included a mixed age group or a variety of indications. The use of 
homografts is associated with slightly higher in-hospital mortality 
rates (2.5–7%) (44–46). Thromboembolic events occur very rarely 
with excellent freedom from late infection (44–46). Structural 
deterioration requiring reintervention seems to be the major issue 
complicating its use (44–46).
The deterioration of homografts, alongside their limited 
availability, resulted in the utilisation of stentless aortic xenografts 
as an alternative. Stentless prostheses are technically demanding too 
but allow improvements in transvalvular gradients and regression 
of left ventricular hypertrophy (47, 48). Another advantage is their 
off-the-shelf availability.
There is limited evidence on stentless valves in young adults, 
most studies reporting mixed ages and/or pathologies. Christ et 
al. (49) reported 188 stentless AVR patients with a mean age of 
53.1 ± 7.1 years and 63.3% stenosis or mixed lesions. Hospital 
mortality was 2.5% for isolated AVR and actuarial survival and 
freedom from reoperation at 10 years were 70 and 83% respectively. 
In another study the same group from Toronto showed excellent 
haemodynamic results without significant rise of transvalvular 
pressure gradients or significant regurgitation until 14 years after 
implantation, and sustained improvements in left ventricular mass 
and function (50).
Bach et al. (51) in a study of the outcomes of stentless valves in 
different age ranges, demonstrated excellent survival for patients aged 
≤60 years compared to those aged ≥61 years. Freedom from cardiac 
death was 94.6 and 70.7%, respectively. Freedom from structural valve 
deterioration was similar between the two age groups (<90%) and 
there was no significant difference in freedom from reoperation at 
12 years between younger and older patients.
Aortic valvulotomy and valvuloplasty
Valvulotomy can be done surgically or percutaneously. Open 
valvulotomy is not common practice in the current era for young 
adults and was previously considered a palliative treatment, with 
reoperation needed in 25–40% of patients with in 10 years (52–54). 
Balloon valvuloplasty can be a safe and effective treatment for children 
presenting with congenital AS. It confers palliative benefits by 
providing a reduction in gradient ranging from 49–70%, thus delaying 
the time for more definite surgical intervention (53, 54). Currently 
this is less appealing compared to other interventions as there is a 
significant risk of developing severe aortic incompetence and there 
is a need for repeat balloon valvulotomy or definitive intervention. 
Percutaneous procedures are used commonly in children but even 
in this subgroup there has been a resurgence of open valvuloplasty, 
even in neonates (54–56).
complete valve Reconstruction
Complete replacement of aortic leaflets was described decades ago 
(57, 58). Initial attempts to use autologous pericardium were associated 
with retraction and fibrosis (57). The technique was abandoned until 
introduction of glutaraldehyde treatment, which has a strengthening 
effect (58). Al Halees et al (59) reported 65 young patients [mean 
age 33 years (12–68)] out of 92 patients who underwent valve 
construction with such autologous pericardial reconstructions; the 
hospital mortality was 2% and at 10 years freedom from reoperation 
was 72% with freedom from structural valve degeneration of 80%.
More recent derivations such as the Ozaki operation may 
potentially play a role in treating young adults. In a series of total 
aortic valve leaflets creation in the young adults subgroup (mean age 
47.8 ± 11.2), there were no in-hospital deaths or thromboembolic 
events, with freedom from reoperation of 98.9% at 76 months of 
follow-up (60).There is increased interest in the Ozaki technique as 
the use of dedicated sizers makes it reproducible plus there is hope 
related to new biomaterials. The use of decellularised matrix for valve 
cusps reconstruction can be an appealing option especially as the 
technology is evolving to aid guided tissue regeneration by means 
of autologous reseeding. The combining of valve reconstruction 
techniques such as Ozaki with decellularised pericardial patch can 
be an interesting development that can provide good alternative to 
conventional valve replacement in young adult as at least it seems it 
can provide adequate haemodynamics with sustained mechanical 
integrity and limited calcifications in animal models (61).
coMpARing AvAilABle SuRgicAl 
optionS
Some direct comparisons have been made between various surgical 
options. Most are retrospective studies in well matched cohorts but 
some randomised studies have been carried out.
Homografts and tissue valves
In young adults it appears that stentless valves may have similar 
clinical performance to homografts during follow up (62, 63). 
The differences between stented and stentless valves are less clear. 
FiguRe 3 |  Actuarial survival after autograft versus homograft aortic root 
replacement (El-Hamamsy et al.) (72) (printed with permission from Lancet).
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There is some evidence demonstrating no significant differences in 
haemodynamic function or clinical events between the two types of 
valves (64, 65), whereas other studies showed better outcomes with 
stentless prostheses (66–68).
conventional AvR vs Ross
There are no randomised studies comparing outcomes of conventional 
AVR to the Ross operation. Propensity-matched cohorts showed no 
differences in mortality or major adverse perioperative outcomes 
in Ross vs mechanical AVR but long-term outcomes are less clear 
(69, 70). Additionally in the Toronto series the Ross procedure was 
better than propensity-matched mechanical AVR in terms of freedom 
from cardiac- and valve-related mortality (69). Even though long-
term survival and freedom from reintervention appear comparable 
between Ross and mechanical AVR, the quality of life after Ross has 
been shown to be superior (21). The Ross procedure is associated 
with improved freedom from cardiac and valve-related mortality and 
a significant reduction in the incidence of stroke and major bleeding 
(17, 19, 71). These are major adverse outcomes that should be taken 
into consideration when considering what the best option is for a 
young adult with decades of life, and thus risk, ahead.
Ross vs Homografts
To date there is only one single centre randomised trial of the Ross 
operation and the comparator procedure was another biological 
root solution (homograft): 216 patients, mean age 38.5 years (72). 
There was no difference in perioperative mortality between Ross and 
homograft (<1 vs 3%, p = 0.621). However, actuarial survival was 
superior in the Ross group at 10 years (97 vs 83%) and similar to an 
age and sex-matched population. Moreover, in multivariate analysis, 
the only independent predictor of late mortality was homograft use 
(Figure 3). This important result from a randomised comparison is 
indicative that selection bias cannot be solely responsible for better 
results in Ross cohorts.
concluSion
Young adults requiring aortic valve intervention represent an 
increasing problem. Guidelines recommend prosthetic replacement 
with either mechanical or tissue valves. This approach is too simplistic 
and is based on studies that were heterogeneous and did not consider 
how the expected long life span for such patients can be adversely 
affected. New evidence confirms that conventional AVR in young 
adults is associated with inferior long-term survival when compared 
to the general population. The main options of mechanical and 
tissue valves are also limited by complications related in the main to 
anticoagulation and accelerated structural degeneration respectively. 
Other options such as stentless valve and homografts can be considered 
but there is no supportive evidence for their superiority to the Ross 
operation, data being generally scarce in young patients. In practice 
homografts are often reserved for patients with endocarditis, which 
may partly explain the higher early mortality (Table 1).
The multitude of options is partly indicative of the lack of strong 
evidence to support one option over the others, the most reliable 
literature being based on matched designs with very few randomised 
trials. There is no ideal valve substitute and it is difficult to provide 
general recommendations in this issue which can explain the 
simplistic approach of the current guidelines. However, there is 
evidence to support the utilisation of the Ross operation in selected 
subset of patients and maybe it can be something that should be 
considered on individual basis, as it does not appear to have any trade-
off between survival and quality of life but it remains an operation 
that can create two valve pathology. Concerns regarding the high 
incidence of reintervention after Ross are not supported with strong 
evidence; reintervention, when needed, can be done safely.
A multi-centre randomised control trial to compare outcomes of 
the Ross procedure with prosthetic valves is needed in this current 
era, as more bioprosthetic valves are implanted in younger patients 
and the role to transcatheter implants is expanding to include 
intermediate risk or even young and low risk patients in the future 
(22, 73). Finally, young patients should be fully informed about all 
the options available - shared decision making is now part of modern 
informed consent. This can be achieved when referring physicians 
have a better understanding of the short and long-term outcomes 
associated with every intervention, in terms of both quantity and 
quality of life (74).
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